| | |
rESWTa (n = 13)
|
LCsIb (n = 12)
|
|---|
|
Outcome variable
|
Follow-up sessions
|
Mean +/− SD
|
p value
|
Mean +/− SD
|
p value
|
|---|
|
Visual analogue scale
|
Baseline
|
2.4 +/− 2.5
| |
2.6 +/− 2.0
| |
|
Week 1
|
1.3 +/− 2.0
|
0.18
|
1.6 +/− 1.7
|
0.08
|
|
Week 4
|
1.3 +/− 1.9
|
0.15
|
1.4 +/− 1.5
|
0.08
|
|
Week 12
|
0.65 +/− 1.2
|
0.022*
|
1.9 +/− 2.7
|
0.52
|
|
Week 24
|
0.35 +/− 0.81c
|
0.0075*
|
1.7 +/− 2.1
|
0.19
|
|
Symptom severity score
|
Baseline
|
21 +/− 6.4
| |
22 +/− 5.1
| |
|
Week 1
|
19 +/− 7.4
|
0.33
|
17 +/− 4.5
|
0.0047*
|
|
Week 4
|
17 +/− 4.3
|
0.031*
|
17 +/− 5.1
|
0.011*
|
|
Week 12
|
15 +/− 4.5
|
0.0082*
|
18 +/− 5.5
|
0.13
|
|
Week 24
|
13 +/− 2.9c
|
0.0059*
|
19 +/− 7.9
|
0.20
|
|
Functional score
|
Baseline
|
14 +/− 3.2
| |
12 +/− 4.1
| |
|
Week 1
|
13 +/− 4.2
|
0.27
|
11 +/− 3.2
|
0.31
|
|
Week 4
|
13 +/− 3.5
|
0.12
|
11 +/− 3.3
|
0.39
|
|
Week 12
|
11 +/− 3.0
|
0.0065*
|
10 +/− 3.4
|
0.19
|
|
Week 24
|
11 +/− 2.2c
|
0.0073*
|
13 +/− 7.0
|
0.65
|
|
Boston questionnaire score
|
Baseline
|
35 +/− 8.5
| |
34 +/− 8.5
| |
|
Week 1
|
32 +/− 10
|
0.28
|
28 +/− 7.0
|
0.037*
|
|
Week 4
|
30 +/− 7.1
|
0.032*
|
28 +/− 8.0
|
0.05
|
|
Week 12
|
26 +/− 6.8
|
0.0040*
|
29 +/− 8.2
|
0.13
|
|
Week 24
|
24 +/− 4.7c
|
0.0037*
|
32 +/− 14
|
0.47
|
|
Peak sensory distal latency
|
Baseline
|
4.5 +/− 0.72
| |
3.7 +/− 1.3
| |
|
Week 12
|
4.1 +/− 0.74d
|
0.0047*
|
3.6 +/− 1.3
|
0.026*
|
|
SNAPe amplitude
|
Baseline
|
17 +/− 6.9
| |
18 +/− 11
| |
|
Week 12
|
18 +/− 6.5d
|
0.66
|
21 +/− 12
|
0.28
|
|
Motor distal latency
|
Baseline
|
4.5 +/− 0.35
| |
4.7 +/− 0.90
| |
|
Week 12
|
4.2 +/− 0.42d
|
0.084
|
4.4 +/− 0.75
|
0.06
|
|
CMAPf amplitude
|
Baseline
|
6.9 +/− 1.5
| |
6.0 +/− 0.61
| |
|
Week 12
|
6.9 +/− 1.6d
|
0.91
|
6.5 +/− 1.2
|
0.20
|
- *p < 0.05
- arESWT = Radial extracorporeal shockwave therapy
- bLCsI = Local corticosteroid injection
- cn = 11
- dn = 10
- eSNAP = Sensory nerve action potential
- fCMAP = Compound muscle action potential
